These effects are likely partly due to local increases in extracellular glutamate causing excitotoxicity, and reduced trophic support [e.g., platelet-derived growth factor (PDGF)] from astrocytes (Tognatta et al., 2020)
plans to test Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports, Reuters (2025) Medicare coverage of GLP-1 drugs, Library of Congress (2024) WEGOVY- semaglutide injection, solution, DailyMed (2024) Supriya Rao, MD, gastroenterologist, director of medical weight loss at Lowell General Hospital, and clinical assistant professor at Tufts University School of Medicine Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Diabetes care 40 , S75S87 (2017)
Whether GLP-1 medications have direct or indirect effects on the menstrual cycle independent of weight loss is a question researchers are now better positioned to study, in part because of work like this